Enterprise Value
-98.65M
Cash
143.7M
Avg Qtr Burn
-14.44M
Short % of Float
0.21%
Insider Ownership
5.96%
Institutional Own.
57.60%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATL001 (cNeT) +/- Nivolumab (anti-PD-1) Details Melanoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
ATL001 (TIL cNeT) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout |